Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference
May 28 2021 - 6:00AM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers, today announced that Anthony Sun, MD, Chairman
and Chief Executive Officer of Zentalis and Melissa Epperly, MBA,
Chief Financial Officer of Zentalis, will participate in a fireside
chat at the Jefferies Virtual Healthcare Conference on Friday, June
4, 2021 at 2:30 p.m. ET.
A live webcast from the Jefferies fireside chat will be
accessible through the Investors section of the Company’s website
at www.zentalis.com. Following the event, an archived webcast will
be available on the Zentalis website.
About Zentalis
Zentalis Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers. The Company is developing a broad pipeline of
potentially best-in-class oncology candidates, including ZN-c5, an
oral selective estrogen receptor degrader (SERD) for ER+/HER2-
breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor
and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New
York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our participation in upcoming events and presentations.
These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to the important factors
discussed under the caption “Risk Factors” in our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2021 filed with the
U.S. Securities and Exchange Commission (SEC) and our other filings
with the SEC. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change.
Investor Contact:
Gitanjali JainSolebury
Trout1.646.378.2949gogawa@soleburytrout.com
Media Contact:
Julia DeutschSolebury
Trout1.646.378.2967jdeutsch@soleburytrout.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2024 to May 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From May 2023 to May 2024